跳至主要内容
临床试验/NCT04135521
NCT04135521已完成不适用

Far Eastern Memorial Hospital

Far Eastern Memorial Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年10月28日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups

研究概览

简要总结

To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.

详细描述

Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II~IV), who had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were included in the study. Patient characteristics, any treatment related side-effects (peri-operative and post-operative complications, chemotherapy related adverse events), treatment response (complete or partial response, stable disease or progressive disease), post-treatment surveillance (disease status: disease-free, recurrence or cancer-related death) will be recorded. Univariate and multivariate logistic regression analysis will be employed to evaluate the survival benefit of the two different chemotherapy methods.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with FIGO stage II~IV ovarian cancer
  • At least one cycle of intravenous dose-dense or intraperitoneal chemotherapy had been administered as the front-line chemotherapy.

排除标准

  • 未提供

结局指标

主要结局

Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups

时间窗: 10 years

months

次要结局

  • Overall survivals between this two groups(10 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sheng-Mou Hsiao

Chief of Department of Obstetrics & Gynecology, Associate Professor

Far Eastern Memorial Hospital

研究点 (1)

Loading locations...

相似试验